The role of fibrinolysis in the therapy of peripheral vascular disease.
In vivo thrombolytic studies in stumptailed monkeys indicated that pentoxifylline potentiates thrombolysis induced by urokinase activated human plasmin. Pentoxifylline as well as prostaglandin E1 released plasminogen activators and activated the fibrinolysin system. From this point of view pentoxifylline and prostaglandin E1 synergized with each other. Pentoxifylline potentiated the thrombolytic effect of prostaglandin E1 in vivo.
D000527:Alprostadil; D000818:Animals; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D004357:Drug Synergism; D005341:Fibrinolysin / Q000627:therapeutic use; D005342:Fibrinolysis / Q000187:drug effects*; D008251:Macaca; D008297:Male; D010431:Pentoxifylline / Q000627:therapeutic use; D011458:Prostaglandins E / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D011458:Prostaglandins E; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator; D000527:Alprostadil; D010431:Pentoxifylline